Casirivimab/imdevimab vs placebo
Development of clinical COVID‐19 symptoms within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab may leads to lower development of clinical COVID‐19 symptoms within 6 months compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes onlyRR 0.02 [0, 0.27]1 study · 969 participantsLow